Infusion therapy generally involves the administration of a medication intravenously. When performing a typical infusion therapy, one or more infusion therapy device (e.g. tubing sets) are used. Oftentimes, during infusion therapy, the end of the tubing set is left exposed to non-sterile surfaces such as when a syringe is removed from a male Luer end of the tubing set. For example, when the end of the tubing set is exposed, the patient or nurse may touch the end, or the end may come in contact with non-sterile bedding, table, or floor surfaces.
Although it is required to clean the hub or needleless connector end of the tubing set, it is not required to clean the other end which is typically a male Luer. Disinfection caps are increasingly being used to disinfect the ends of infusion therapy devices such as needleless connectors, IV sets, or short extension tubing. Such caps generally include foam soaked with alcohol which contacts surfaces of the port when the cap is connected to the port. Various problems exist when using these caps. For example, the alcohol soaked foam only contacts exterior surfaces of the access port. Also, once a cap is placed on a port, the alcohol in the cap evaporates quickly. Further, use of alcohol often results in alcohol being forced into the IV line.
Further, some types of female Luer connectors trap liquids which are incapable of being effectively treated by conventional disinfection caps. For example, side ports on a catheter adapter are commonly used as a quick access for IV medications or fluid injection into an IV line, or into the patient's bloodstream, for quick effects, especially in emergency situations. The port may be accessed multiple times during the entire use of a catheter; sometimes in excess of seven days. Contaminated Luer access devices, such as a syringe, when connected to the port may transfer microorganisms the side wall and bottom of the side port. This may result in microorganism growth and colonization inside the port, which poses a risk of infection for the patient. Currently available disinfections caps are not able to effectively disinfect these surfaces.
Thus, while methods and systems currently exist for disinfecting needleless connectors, challenges still exist. Accordingly, it would be an improvement in the art to augment or replace current techniques with the systems and methods discussed herein.
The present invention relates to a cap for a medical connector. More specifically, the present invention related to an antimicrobial cap for placement over a connector, wherein various features of the antimicrobial cap maintain the connector in an antiseptic state.
Some implementations of the present invention provide an antimicrobial cap having an inner surface on which is disposed a dry, non-bonded antimicrobial material. Upon exposure to a residual fluid, the dry, non-bonded antimicrobial material is quickly dissolved, thereby forming an antimicrobial solution within the closed volume of the cap. The antimicrobial solution contacts the inner surface of the cap and the outer surfaces of a connector inserted within the interior of the cap.
Other implementations of the present invention provide various clip features on the outer surface of an antimicrobial cap, wherein the clip feature allow the cap to be attached to a section of IV tubing, or an IV pole to prevent the cap from contacting an undesired surface, such as the ground. Various structures are further provided for storing and dispensing the antimicrobial caps to a clinician.
Some implementations of the present invention further comprise an antimicrobial cap having an antimicrobial plug. The antimicrobial plug extends outwardly from the inner, base surface of the cap and extends into an interior volume of a connector having an interior space into which the plug may extend. The antimicrobial plug may comprise various shapes and configurations to maximize surface area without compromising the function of the cap and/or the connector.
In some instances, an antimicrobial cap is provided having a removable/disposable antimicrobial plug. The removable plug is inserted into the cap via a hole provided in the base of the cap, opposite the opening of the cap. The plug may be inserted, used, and then removed to maintain adequate antimicrobial effect.
Some implementations of the instant invention comprise an antimicrobial growth material that is attached to the inner surface of the cap's base. The growth material comprises an antimicrobial agent or coating that is eluted from the material when contacted by a residual fluid. The growth material is dehydrated and swells or grows when exposed to a liquid.
Further, some implementations of the instant invention comprise a cap having an inner surface on which is disposed an antimicrobial lubricant. The antimicrobial lubricant is transferred to the outer and inner surfaces of a connector when the cap is placed thereon. Upon removal of the cap, the antimicrobial lubricant remains on the cap and connector surfaces, thereby imparting an antimicrobial effect.
This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This Summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.
Additional features and advantages of the invention will be set forth in the description which follows, and in part will be obvious from the description, or may be learned by the practice of the invention. The features and advantages of the invention may be realized and obtained by means of the instruments and combinations particularly pointed out in the appended claims. These and other features of the present invention will become more fully apparent from the following description and appended claims, or may be learned by the practice of the invention as set forth hereinafter.
In order to describe the manner in which the above-recited and other advantages and features of the invention can be obtained, a more particular description of the invention briefly described above will be rendered by reference to specific embodiments thereof which are illustrated in the appended drawings. Understanding that these drawings depict only typical embodiments of the invention and are not therefore to be considered to be limiting of its scope, the invention will be described and explained with additional specificity and detail through the use of the accompanying drawings in which:
The present invention relates to a cap for a medical connector. More specifically, the present invention related to an antimicrobial cap for placement over a connector, wherein various features of the antimicrobial cap maintain the connector in an antiseptic state.
As used herein the term “connector” is understood to include any structure that is part of an intravenous device that is capable of making a connection with a secondary intravenous device. Non-limiting examples of connectors in accordance with the present invention include needleless connectors, male Luer connectors, female Luer connectors, side port valves, y-port valves, port valves, and other similar structures.
Referring now to
In some embodiments, cap 10 receives connector 30 via a threaded connection. For example, in some instances cap 10 comprises a set of internal or external threads that are threadedly engaged by a complementary set of threads located on the connector. In other instances, cap 10 receives connector 30 via a friction or interference fit.
Antimicrobial cap 10 further comprises an inner surface 14 defining a volume sufficient to receive connector 30. Inner surface 14 is generally tubular, however in some instances inner surface 14 tapers inwardly from opening 12 to the cap's base 16. Inner surface 14 may include any geometry or shape as may be desired.
The volume of cap 10 comprises the interior space of cap 10 extending from opening 12 to base 16. The volume is generally selected to admit placement of connector 30 within cap 10 for the purpose of maintaining cap 10 in an antiseptic condition. Accordingly, antimicrobial cap 10 further comprises a quantity of antimicrobial material 20 applied to inner surface 14. Antimicrobial material 20 may comprise any type or form of antimicrobial material that is safe for use in accordance with the teachings of the present invention. For example, in some instances antimicrobial material 20 is selected from a group consisting of chlorhexidine diacetate, chlorhexidine gluconate, alexidine, silver sulfadiazine, silver acetate, silver citrate hydrate, cetrimide, cetyl pyridium chloride, benzalkonium chloride, o-phthalaldehyde, and silver element.
In some embodiments, antimicrobial material 20 comprises a dry, non-bonded coating that is applied to inner surface 14 by a known method. For instance, in some embodiments antimicrobial material 20 is applied to inner surface 14 by spraying, dipping or brushing. In other instances, antimicrobial material 20 comprises a UV cured polymer matrix in which an antimicrobial agent is uniformly dispersed. The antimicrobial agent is not chemically bound to the polymer matrix, and therefore is capable of being eluted out of the matrix when the matrix is exposed to, or wetted by a residual fluid.
When cap 10 is placed onto connector 30, connector 30 reduces the volume of cap 10. Once secured together, connector 30 and antimicrobial cap 10 form a closed volume between the interconnected devices. Upon exposure to a residual fluid 32 from connector 30, the dry, non-bonded antimicrobial material 20 is rapidly dissolved by residual fluid 32, thereby forming an antimicrobial solution with the residual fluid 32 within the closed volume, as shown in
As discussed above, in some instances antimicrobial material 20 comprises a UV cured, hydrophilic polymer material that forms a matrix comprising a plurality of microscopic interstices in which an antimicrobial agent is evenly dispersed (not shown). Upon exposure to residual fluid 32, the polymer matrix is softened and penetrated by the residual fluid. The antimicrobial agent within the polymer matrix is eluted out of the matrix and into the residual fluid to form an antimicrobial solution have a desired final concentration within the closed volume. Examples of suitable polymer materials are provided in U.S. patent application Ser. Nos. 12/397,760, 11/829,010, 12/476,997, 12/490,235, and 12/831,880, each of which is incorporated herein in their entireties.
Generally, a quantity or amount of antimicrobial material 20 is applied to inner surface so that upon being dissolved in residual fluid 32 within the closed volume, an antimicrobial solution is provided having a minimum concentration required to have sufficient antimicrobial efficacy within the closed volume. In some instances, a predetermined quantity or amount of antimicrobial material 20 is applied to inner surface 14 to provide a final concentration from approximately 0.005% w/w to approximately 25% w/w. Thus, the quantity or amount of antimicrobial material 20 is determined based upon the calculated closed volume of antimicrobial cap 10 and connector 30.
For example, if the volume of antimicrobial cap 10 is 1 cm3, and the volume of the portion of connector 30 that is inserted into cap 10 is 0.75 cm3, then the calculated closed volume of antimicrobial cap 10 is 0.25 cm3. Thus, the maximum possible volume of residual fluid 32 within the closed volume is 0.25 cm3. Accordingly, to achieve a final, desired concentration of antimicrobial material within the antimicrobial solution from approximately 0.005% w/w to approximately 25% w/w (within the closed volume), approximately 12.6 μg to approximately 83.3 mg of antimicrobial material 20 will need to be applied to inner surface 14.
Residual fluid 32 may comprise any fluid or combination of fluids common to infusion therapy procedures. For example, in some embodiments residual fluid 32 comprises blood, a medicament, water, saline, urine, or combinations thereof. In some instances, a residual fluid 32 leaks into antimicrobial cap 10 after connector 30 has been inserted into cap 10. In other instance, a residual fluid 32 is present on connector 30 prior to being inserted into cap 10. Further, in some instances a residual fluid 32 is present in antimicrobial cap 10 prior to connector 30 being inserted therein.
Following use of antimicrobial cap 10, cap 10 is removed from connector 30 and is disposed. In some instances, antimicrobial cap 10 is reused multiple times prior to being disposed. For example, in some instances cap 10 is applied to connector 30 after connector 30 is removed from a separate connector (not shown). Prior to reconnecting connector 30 to the separate connector, antimicrobial cap 10 is again removed from connector 30, and reapplied following removal of connector 30 from the separate connector.
In some instances, the exterior 18 of antimicrobial cap 10 further comprises a clip 40 having a surface 42 for receiving at least one of an IV line, and an IV pole to maintain a desired position of antimicrobial cap 10, as shown in
Referring now to
In other instances, the exterior surfaces 18 of antimicrobial caps 10 are tapered inwardly from opening 12 to base 16, wherein the diameter of base 16 is less than the diameter of opening 12, as shown in
Further, in some instances a caddy 80 is provided having opposing surfaces 82 on which the base surfaces 16 of multiple caps 10 are temporarily adhered with a weak adhesive, as shown in
Referring now generally to
With specific reference to
Side port 130 comprises an opening or aperture 132, an internal volume 134, and a bottom 136. In some instances, internal volume 134 may further comprise a unique internal geometry, as discussed below. Side port 130 further comprises a port valve 138 that forms a defeatable seal between side port 130 and an interior lumen of catheter adapter 120. Upon injecting a fluid into side port 130, port valve 138 is temporarily defeated to break the seal and permit the injected fluid to bypass port valve 138 and enter the interior lumen of catheter adapter 120. Following the injection, a small aliquot of residual fluid is typically left in internal volume 134, and may be susceptible to microbial contamination. This residual fluid typically pools and gathers at the bottom 136 of side port 130 and contacts the outer surface of port valve 138. However, larger volumes of residual fluid may contact additional surfaces of internal volume 134, and may even fill or substantially fill internal volume 134.
Antimicrobial cap 100 further comprises an antimicrobial plug 110. Antimicrobial plug 110 generally comprises an antimicrobial material or coating that is readily dissolved or eluted when plug 110 contacts a residual fluid in internal volume 134. In some instances, antimicrobial plug 110 comprises a UV cured, hydrophilic material in which is evenly dispersed an antimicrobial agent, as described above. In other instances, plug 110 is comprised of a solid antimicrobial material. In other instances, plug 110 comprises a polymer tube having an antimicrobial coating.
Antimicrobial plug 110 may comprise any form or shape that is compatible with the teachings of the present invention. For example, in some instances plug 110 comprises a tubular shape. In other instances plug 110 comprises a rod. Further, in some instances antimicrobial plug 110 comprises a non-linear shape or design, as shown and discussed in connection with
Antimicrobial plug 110 comprises a proximal end 112 that is attached to base 106 of cap 100, and further comprises a distal end 114 that extends outwardly from base 106. Plug 110 comprises a length and diameter sufficient to be inserted through aperture 132 and positioned within internal volume 134 such that distal end 114 is positioned in proximity with bottom 136 when cap 100 is coupled to side port 130, as shown in
The length and diameter of plug 110 is selected to maximize the surface area of plug 110 without compromising the ability of cap 100 to be hingedly closed over side port 130. In some instances plug 110 comprises an outer diameter of approximately 0.076 inches and a functional height of approximately 0.338 inches.
In some instances it may be desirable to increase the surface area of antimicrobial plug 110 while still maintaining the functionality of the hinged connection. Accordingly, in some embodiments antimicrobial plug 110 is curved, as shown in
In other instances, distal end 114 further comprises a disc 116 having an increased diameter that is slightly less than the diameter of bottom 136, as shown in
In some embodiments, internal volume 134 comprises a unique, internal geometry 140 having various surfaces, as shown in
Some implementations of the present invention further comprise a cap 200 having a hole 220 in the cap's base 216, as shown in
Cap 200 is assembled by inserting distal end 214 into and through hole 220 until proximal end 212 is fully seated into recess 217 of base 216, as shown in
In some embodiments, multiple antimicrobial plugs are provided from which a user may select and insert into hole 220. For example, in some instances a plurality of plugs are provided, wherein each plug comprises a unique or different antimicrobial agent. Antimicrobial plug 210 may also comprise various non-linear shapes, such as a spiral shape or wavy shape, as demonstrated in
Some implementations of the present invention further comprise a cap 300 comprising a base surface 316 on which is providing a dehydrated antimicrobial material 380, as shown in
Material 380 further comprises an antimicrobial agent 320, or an antimicrobial coating comprising an antimicrobial agent that is dissolved or eluted when material 380 is exposed to residual liquid 32, thereby swelling or undergoing an expansive growth, as shown in
Further, in some instances the inner surface 404 of cap 400 comprises an antimicrobial lubricant 450, as shown in
A portion of antimicrobial lubricant 450 is transferred to the outer and inner surfaces of side port 130 as cap 400 is placed onto side port 130, as shown in
One having skill in the art will appreciate that the various other embodiments of the present invention may similarly be coated with an antimicrobial lubricant, thereby further adding a contact kill effect to the device. Thus, the features of the various embodiments of the present invention may be interchangeably implemented to provide a wide variety of antimicrobial caps and other devices.
Various embodiments of the present invention may be manufactured according to know methods and procedures. In some instances, an antimicrobial component is comprises of an antimicrobial material. In other instances, an antimicrobial component is extruded or molded of base polymer materials that have good bond strength to an antimicrobial material or agent, such as polycarbonate, copolyester, ABS, PVC, and polyurethane. The base polymer structure may be coated with an adhesive-based antimicrobial material, which may have elution characteristics. In some instances, the topology and dimensions of the base polymer structure are optimized for microbiology efficacy, lasting elution profiles, and assembly geometry constraints.
Various antimicrobial components of the instant invention may be casted or molded directly of antimicrobial material. In some instances, the antimicrobial component is casted in plastic and subsequently coated with an antimicrobial material. In some embodiments, an antimicrobial component is grown directly onto another component of the device. For example, in some instances an antimicrobial plug is grown directly from the inner or base surface of the cap. This is done by first placing a peel-away sleeve on the base surface of the cap. The antimicrobial material is deposited into the lumen formed by the sleeve. After curing is complete, the sleeve is peeled away, thereby revealing the plug on the base surface of the cap.
In other instances, various components of the device are joined together via an adhesive or epoxy. For example, in some instances an antimicrobial plug is initially casted or molded, and then coated with an antimicrobial coating or material. The coated plug is then adhered to the base surface of the cap by an epoxy. For the disc-end antimicrobial plugs, the disc and the rod or tube may be cast as a whole piece, or may be case or molded separately and then subsequently bonded together.
Antimicrobial components and coatings of the instant invention may be comprised of one or multiple antimicrobial agents in a polymer matrix. The polymer matrix may be adhesive-based, with a preference to acrylate- or cyanoacrylate-based adhesives for good bond strength and fast elution rates. Solvents may be added to increase bonding. Non-limiting examples of suitable antimicrobial material compositions are provided in United States Published Patent Application Nos. 2010/0137472, and 2010/0135949, each of which is incorporated herein by reference in their entireties.
The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.
This application is a continuation of U.S. application Ser. No. 14/260,027, filed Apr. 23, 2014, and titled ANTIMICROBIAL CAPS FOR MEDICAL CONNECTORS, which is incorporated herein in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
1844023 | Terry | Feb 1932 | A |
3223629 | Loeffler | Dec 1965 | A |
3352531 | Kilmarx | Nov 1967 | A |
3598127 | Wepsic | Aug 1971 | A |
3695921 | Shepherd et al. | Oct 1972 | A |
3867937 | Schwarts | Feb 1975 | A |
3986508 | Barrington | Oct 1976 | A |
4068660 | Beck | Jan 1978 | A |
4170996 | Wu | Oct 1979 | A |
4280500 | Ono | Jul 1981 | A |
4334551 | Pfister | Jun 1982 | A |
4339336 | Hammond et al. | Jul 1982 | A |
4387879 | Tauschinski | Jun 1983 | A |
4449693 | Gereg | May 1984 | A |
4469483 | Becker et al. | Sep 1984 | A |
4512766 | Vaillancourt | Apr 1985 | A |
4584192 | Dell et al. | Apr 1986 | A |
4585435 | Vaillancourt | Apr 1986 | A |
4592920 | Murtfeldt | Jun 1986 | A |
4603152 | Laurin et al. | Jul 1986 | A |
4610674 | Suzuki et al. | Sep 1986 | A |
4629743 | Michl | Dec 1986 | A |
4629746 | Michi | Dec 1986 | A |
4642126 | Zador et al. | Feb 1987 | A |
4676782 | Yamamoto et al. | Jun 1987 | A |
4677143 | Laurin et al. | Jun 1987 | A |
4716032 | Westfall et al. | Dec 1987 | A |
4723948 | Clark et al. | Feb 1988 | A |
4758225 | Cox et al. | Jul 1988 | A |
4781703 | Walker et al. | Nov 1988 | A |
4798594 | Hillstead | Jan 1989 | A |
4805933 | Swisher | Feb 1989 | A |
4838873 | Landskron et al. | Jun 1989 | A |
4842591 | Luther | Jun 1989 | A |
4846812 | Walker et al. | Jul 1989 | A |
4874377 | Newgard et al. | Oct 1989 | A |
4880414 | Whipple | Nov 1989 | A |
4895566 | Lee | Jan 1990 | A |
4897427 | Bamavon et al. | Jan 1990 | A |
4915934 | Tomlinson | Apr 1990 | A |
4917668 | Haindl | Apr 1990 | A |
4925668 | Khan et al. | May 1990 | A |
4933178 | Capelli | Jun 1990 | A |
4935010 | Cox et al. | Jun 1990 | A |
4950257 | Hibbs et al. | Aug 1990 | A |
4955890 | Yamamoto et al. | Sep 1990 | A |
4976697 | Walder et al. | Dec 1990 | A |
4985399 | Matsuda et al. | Jan 1991 | A |
4990357 | Karakelle et al. | Feb 1991 | A |
5019096 | Fox, Jr. et al. | May 1991 | A |
5023082 | Friedman et al. | Jun 1991 | A |
5030665 | Lee | Jul 1991 | A |
5041097 | Johnson | Aug 1991 | A |
5053014 | Van Heugten | Oct 1991 | A |
5062836 | Wendell | Nov 1991 | A |
5064416 | Newgard et al. | Nov 1991 | A |
5077352 | Elton | Dec 1991 | A |
5078703 | Bryant | Jan 1992 | A |
5084023 | Lemieux | Jan 1992 | A |
5085645 | Purdy et al. | Feb 1992 | A |
5098405 | Peterson et al. | Mar 1992 | A |
5098410 | Kerby et al. | Mar 1992 | A |
5108374 | Lemieux | Apr 1992 | A |
5127905 | Lemieux | Jul 1992 | A |
5129887 | Euteneuer et al. | Jul 1992 | A |
5154703 | Bonaldo | Oct 1992 | A |
5156596 | Balbierz et al. | Oct 1992 | A |
5167647 | Wijkamp et al. | Dec 1992 | A |
5217493 | Raad et al. | Jun 1993 | A |
5226898 | Gross | Jul 1993 | A |
5234410 | Graham et al. | Aug 1993 | A |
5242425 | White et al. | Sep 1993 | A |
5256145 | Atkinson et al. | Oct 1993 | A |
5290246 | Yamamoto et al. | Mar 1994 | A |
5295969 | Fischell et al. | Mar 1994 | A |
5330435 | Vaillancourt | Jul 1994 | A |
5330449 | Prichard et al. | Jul 1994 | A |
5350363 | Goode et al. | Sep 1994 | A |
5352205 | Dales et al. | Oct 1994 | A |
5357636 | Dresdner, Jr. et al. | Oct 1994 | A |
5366505 | Farber | Nov 1994 | A |
5380301 | Prichard et al. | Jan 1995 | A |
5405323 | Rogers et al. | Apr 1995 | A |
5405338 | Kranys | Apr 1995 | A |
5456675 | Wolbring et al. | Oct 1995 | A |
5456948 | Mathisen et al. | Oct 1995 | A |
5458640 | Gerrone | Oct 1995 | A |
5470319 | Mayer | Nov 1995 | A |
5487728 | Vaillancourt | Jan 1996 | A |
5512199 | Khan et al. | Apr 1996 | A |
5520666 | Choudhury et al. | May 1996 | A |
5536258 | Folden | Jul 1996 | A |
5540661 | Tomisaka et al. | Jul 1996 | A |
5547662 | Khan et al. | Aug 1996 | A |
5549566 | Elias et al. | Aug 1996 | A |
5549577 | Siegel et al. | Aug 1996 | A |
5575769 | Vaillancourt | Nov 1996 | A |
5589120 | Khan et al. | Dec 1996 | A |
5613663 | Schmidt et al. | Mar 1997 | A |
5616338 | Fox, Jr. et al. | Apr 1997 | A |
5620434 | Brony | Apr 1997 | A |
5629006 | Hoang et al. | May 1997 | A |
5638812 | Turner | Jun 1997 | A |
5651772 | Arnett | Jul 1997 | A |
5653695 | Hopkins et al. | Aug 1997 | A |
5657963 | Hinchliffe et al. | Aug 1997 | A |
5658253 | Piontek et al. | Aug 1997 | A |
5676656 | Brimhall | Oct 1997 | A |
5688747 | Khan et al. | Nov 1997 | A |
5697915 | Lynn | Dec 1997 | A |
5698229 | Ohsumi et al. | Dec 1997 | A |
5712229 | Hopkins et al. | Jan 1998 | A |
5716406 | Farber | Feb 1998 | A |
5718678 | Fleming, III | Feb 1998 | A |
5738144 | Rogers | Apr 1998 | A |
5749861 | Guala et al. | May 1998 | A |
5763412 | Khan et al. | Jun 1998 | A |
5773487 | Sokoi | Jun 1998 | A |
5806831 | Paradis | Sep 1998 | A |
5810768 | Lopez | Sep 1998 | A |
5817069 | Arnett | Oct 1998 | A |
5827239 | Dillon et al. | Oct 1998 | A |
5830196 | Hicks | Nov 1998 | A |
5830401 | Prichard et al. | Nov 1998 | A |
5833674 | Trumbull et al. | Nov 1998 | A |
5843046 | Motisi et al. | Dec 1998 | A |
5861440 | Gohla et al. | Jan 1999 | A |
5911710 | Barry et al. | Jun 1999 | A |
5944712 | Frassica et al. | Aug 1999 | A |
5951519 | Utterberg | Sep 1999 | A |
5954698 | Pike | Sep 1999 | A |
5957898 | Jepson et al. | Sep 1999 | A |
5967490 | Pike | Oct 1999 | A |
6039302 | Cote, Sr. et al. | Mar 2000 | A |
6046143 | Khan et al. | Apr 2000 | A |
6050978 | Orr et al. | Apr 2000 | A |
6051609 | Yu et al. | Apr 2000 | A |
6068622 | Sater et al. | May 2000 | A |
6074379 | Prichard | Jun 2000 | A |
6077244 | Botich et al. | Jun 2000 | A |
6082490 | Rowland | Jul 2000 | A |
6102890 | Stivland et al. | Aug 2000 | A |
6117108 | Woehr et al. | Sep 2000 | A |
6120784 | Snyder, Jr. | Sep 2000 | A |
6127320 | van Ooij et al. | Oct 2000 | A |
6156054 | Zadno-Azizi et al. | Dec 2000 | A |
6165168 | Russo | Dec 2000 | A |
6171287 | Lynn et al. | Jan 2001 | B1 |
6217566 | Ju et al. | Apr 2001 | B1 |
6228073 | Noone et al. | May 2001 | B1 |
6242526 | Siddiqui et al. | Jun 2001 | B1 |
6245098 | Feeser et al. | Jun 2001 | B1 |
6248811 | Ottersbach et al. | Jun 2001 | B1 |
6273404 | Holman et al. | Aug 2001 | B1 |
6273869 | Vaillancourt | Aug 2001 | B1 |
6322847 | Zhong et al. | Nov 2001 | B1 |
6326417 | Jia | Dec 2001 | B1 |
6332874 | Eliasen et al. | Dec 2001 | B1 |
6337357 | Fukunishi et al. | Jan 2002 | B1 |
6344218 | Dodd et al. | Feb 2002 | B1 |
6353041 | Qian | Mar 2002 | B1 |
6387075 | Stivland et al. | May 2002 | B1 |
6394983 | Mayoral | May 2002 | B1 |
6413539 | Shalaby | Jul 2002 | B1 |
6426373 | Stange et al. | Jul 2002 | B1 |
6475434 | Darouiche | Nov 2002 | B1 |
6485473 | Lynn | Nov 2002 | B1 |
6488942 | Ingemann | Dec 2002 | B1 |
6492445 | Siddiqui et al. | Dec 2002 | B2 |
6503353 | Peterson et al. | Jan 2003 | B1 |
6511462 | Itou et al. | Jan 2003 | B1 |
6544214 | Utterberg | Apr 2003 | B1 |
6575958 | Happ et al. | Jun 2003 | B1 |
6575960 | Becker et al. | Jun 2003 | B2 |
6576633 | Young et al. | Jun 2003 | B1 |
6579221 | Peterson | Jun 2003 | B1 |
6579539 | Lawson et al. | Jun 2003 | B2 |
6595981 | Huet | Jul 2003 | B2 |
6663614 | Carter | Dec 2003 | B1 |
6699221 | Vaillancourt | Mar 2004 | B2 |
6719726 | Meng et al. | Apr 2004 | B2 |
6719991 | Darouiche et al. | Apr 2004 | B2 |
6723350 | Burrell et al. | Apr 2004 | B2 |
6740063 | Lynn | May 2004 | B2 |
6808161 | Hishikawa | Oct 2004 | B1 |
6843784 | Modak et al. | Jan 2005 | B2 |
6846846 | Modak et al. | Jan 2005 | B2 |
6861060 | Luriya et al. | Mar 2005 | B1 |
6883778 | Newton et al. | Apr 2005 | B1 |
6887270 | Miller et al. | May 2005 | B2 |
6893456 | Lumauig | May 2005 | B2 |
6896889 | Chevalier et al. | May 2005 | B2 |
7008404 | Nakajima | Mar 2006 | B2 |
7074839 | Fansler et al. | Jul 2006 | B2 |
7098256 | Ong et al. | Aug 2006 | B2 |
7115183 | Larson et al. | Oct 2006 | B2 |
7179849 | Terry | Feb 2007 | B2 |
7198800 | Ko | Apr 2007 | B1 |
7232428 | Inukai et al. | Jun 2007 | B1 |
7232540 | Gould et al. | Jun 2007 | B2 |
7261925 | Nesbit | Aug 2007 | B2 |
7268165 | Greten et al. | Sep 2007 | B2 |
7347839 | Hiejima | Mar 2008 | B2 |
7374798 | Choo et al. | May 2008 | B2 |
7396346 | Nakajima | Jul 2008 | B2 |
7407707 | Gould et al. | Aug 2008 | B2 |
7462401 | Halfyard et al. | Dec 2008 | B2 |
7470254 | Basta et al. | Dec 2008 | B2 |
7494339 | Dias et al. | Feb 2009 | B2 |
7498367 | Qian | Mar 2009 | B2 |
7514477 | Klare et al. | Apr 2009 | B2 |
7608082 | Cuevas et al. | Oct 2009 | B2 |
7682340 | Funamura et al. | Mar 2010 | B2 |
7704935 | Davis et al. | Apr 2010 | B1 |
7736339 | Woehr et al. | Jun 2010 | B2 |
7816434 | Hackbarth et al. | Oct 2010 | B2 |
7871649 | Modak et al. | Jan 2011 | B2 |
7874467 | Pardes et al. | Jan 2011 | B2 |
7914494 | Hiejima | Mar 2011 | B2 |
7981475 | Takahashi | Jul 2011 | B2 |
8034454 | Terry | Oct 2011 | B2 |
8034455 | Wang et al. | Oct 2011 | B2 |
8067402 | Whiteford et al. | Nov 2011 | B2 |
8133423 | Tang et al. | Mar 2012 | B2 |
8227050 | O'Neil | Jul 2012 | B1 |
8231602 | Anderson | Jul 2012 | B2 |
8263102 | Labrecque et al. | Sep 2012 | B2 |
8268381 | Whiteford et al. | Sep 2012 | B2 |
8343523 | Toreki et al. | Jan 2013 | B2 |
8343525 | Davis et al. | Jan 2013 | B2 |
8353876 | Suwito et al. | Jan 2013 | B2 |
8357119 | Stout et al. | Jan 2013 | B2 |
8388583 | Stout et al. | Mar 2013 | B2 |
8414547 | DiFiore et al. | Apr 2013 | B2 |
8512294 | Ou-Yang et al. | Aug 2013 | B2 |
8574171 | Nesbitt et al. | Nov 2013 | B2 |
8622995 | Ziebol et al. | Jan 2014 | B2 |
8622996 | Ziebol et al. | Jan 2014 | B2 |
8691887 | Ou-Yang | Apr 2014 | B2 |
8728030 | Woehr | May 2014 | B2 |
8840927 | DiTizio et al. | Sep 2014 | B2 |
9028425 | Burkholz | May 2015 | B2 |
9078441 | Raad | Jul 2015 | B2 |
9138252 | Bierman et al. | Sep 2015 | B2 |
9259284 | Rogers | Feb 2016 | B2 |
9750928 | Burkholz et al. | Sep 2017 | B2 |
10493244 | Peterson et al. | Dec 2019 | B2 |
20010010016 | Modak et al. | Jul 2001 | A1 |
20010016589 | Modak et al. | Aug 2001 | A1 |
20010018095 | Shienker et al. | Aug 2001 | A1 |
20010020153 | Howell | Sep 2001 | A1 |
20010032006 | Griffin et al. | Oct 2001 | A1 |
20010049519 | Holman et al. | Dec 2001 | A1 |
20010053895 | Vaillancourt | Dec 2001 | A1 |
20010056133 | Montgomery | Dec 2001 | A1 |
20020009436 | Doyle et al. | Jan 2002 | A1 |
20020022660 | Jampani et al. | Feb 2002 | A1 |
20020028751 | Lokkesmoe et al. | Mar 2002 | A1 |
20020037260 | Budny et al. | Mar 2002 | A1 |
20020040092 | Siddiqui et al. | Apr 2002 | A1 |
20020064858 | Yacoby-Zeevi | May 2002 | A1 |
20020091424 | Biel | Jul 2002 | A1 |
20020119111 | Kilgour et al. | Aug 2002 | A1 |
20020133124 | Leinsing et al. | Sep 2002 | A1 |
20020144705 | Brattesani et al. | Oct 2002 | A1 |
20030023208 | Osypka et al. | Jan 2003 | A1 |
20030060804 | Vaillancourt | Mar 2003 | A1 |
20030068667 | Olson et al. | Apr 2003 | A1 |
20030072781 | Pelerin | Apr 2003 | A1 |
20030105143 | Ammendola et al. | Jun 2003 | A1 |
20030119932 | Al-Akhdar et al. | Jun 2003 | A1 |
20030134783 | Harshey et al. | Jul 2003 | A1 |
20030144362 | Utterberg et al. | Jul 2003 | A1 |
20030147932 | Nun et al. | Aug 2003 | A1 |
20030162839 | Symington et al. | Aug 2003 | A1 |
20030170308 | Cleary et al. | Sep 2003 | A1 |
20030176848 | Gibson et al. | Sep 2003 | A1 |
20030206875 | Budny et al. | Nov 2003 | A1 |
20030215433 | Kokai-Kun et al. | Nov 2003 | A1 |
20030224032 | Read et al. | Dec 2003 | A1 |
20040013574 | Conway | Jan 2004 | A1 |
20040013703 | Ralph et al. | Jan 2004 | A1 |
20040014864 | Milic et al. | Jan 2004 | A1 |
20040039349 | Modak et al. | Feb 2004 | A1 |
20040058829 | Hei et al. | Mar 2004 | A1 |
20040062592 | Shekalim et al. | Apr 2004 | A1 |
20040109852 | Xu | Jun 2004 | A1 |
20040115477 | Nesbit | Jun 2004 | A1 |
20040132164 | Doyle et al. | Jul 2004 | A1 |
20040180829 | Bassler et al. | Sep 2004 | A1 |
20040185296 | Mazzanti | Sep 2004 | A1 |
20040230162 | Tan | Nov 2004 | A1 |
20040234475 | Lannibois-Drean et al. | Nov 2004 | A1 |
20050008671 | Van Antwerp | Jan 2005 | A1 |
20050048005 | Stockel | Mar 2005 | A1 |
20050048124 | Sarangapani | Mar 2005 | A1 |
20050059731 | Albrecht et al. | Mar 2005 | A1 |
20050080158 | Ong et al. | Apr 2005 | A1 |
20050100580 | Osborne et al. | May 2005 | A1 |
20050118239 | Sabesan | Jun 2005 | A1 |
20050124970 | Kunin et al. | Jun 2005 | A1 |
20050131356 | Ash et al. | Jun 2005 | A1 |
20050143286 | Singh et al. | Jun 2005 | A1 |
20050147525 | Bousquet | Jul 2005 | A1 |
20050148928 | Molina et al. | Jul 2005 | A1 |
20050158253 | Budney et al. | Jul 2005 | A1 |
20050176905 | Moon et al. | Aug 2005 | A1 |
20050209581 | Butts et al. | Sep 2005 | A1 |
20050209583 | Powers et al. | Sep 2005 | A1 |
20050233950 | Madhyastha | Oct 2005 | A1 |
20050265931 | Qian | Dec 2005 | A1 |
20060024372 | Utterberg et al. | Feb 2006 | A1 |
20060051385 | Scholz | Mar 2006 | A1 |
20060064159 | Porter et al. | Mar 2006 | A1 |
20060163515 | Ruschke | Jul 2006 | A1 |
20060165751 | Chudzik et al. | Jul 2006 | A1 |
20060165903 | Mazzanti | Jul 2006 | A1 |
20060177477 | Ash et al. | Aug 2006 | A1 |
20060239954 | Sancho | Oct 2006 | A1 |
20060258780 | Chaussade et al. | Nov 2006 | A1 |
20060259012 | Propp et al. | Nov 2006 | A1 |
20060259032 | Nesbitt | Nov 2006 | A1 |
20060281663 | Asmus | Dec 2006 | A1 |
20070000407 | Leong | Jan 2007 | A1 |
20070083157 | Belley et al. | Apr 2007 | A1 |
20070083162 | O'Reagan et al. | Apr 2007 | A1 |
20070093762 | Utterberg et al. | Apr 2007 | A1 |
20070112112 | Kerschner et al. | May 2007 | A1 |
20070112146 | Falk et al. | May 2007 | A1 |
20070129690 | Rosenblatt et al. | Jun 2007 | A1 |
20070141524 | Brennan et al. | Jun 2007 | A1 |
20070154621 | Raad | Jul 2007 | A1 |
20070160547 | Duffy et al. | Jul 2007 | A1 |
20070166344 | Qu et al. | Jul 2007 | A1 |
20070202177 | Hoang | Aug 2007 | A1 |
20070203574 | McGrath et al. | Aug 2007 | A1 |
20070225179 | Schutz et al. | Sep 2007 | A1 |
20070233007 | Adams | Oct 2007 | A1 |
20070275101 | Lu et al. | Nov 2007 | A1 |
20070281198 | Lousenberg | Dec 2007 | A1 |
20080026026 | Lu et al. | Jan 2008 | A1 |
20080027410 | Harding et al. | Jan 2008 | A1 |
20080033371 | Updegraff et al. | Feb 2008 | A1 |
20080039796 | Nakajima | Feb 2008 | A1 |
20080051737 | Paul et al. | Feb 2008 | A1 |
20080075761 | Modak et al. | Mar 2008 | A1 |
20080103487 | Susumu | May 2008 | A1 |
20080108944 | Woehr et al. | May 2008 | A1 |
20080119789 | Kaemmerer | May 2008 | A1 |
20080161763 | Harding | Jul 2008 | A1 |
20080182921 | Suh et al. | Jul 2008 | A1 |
20080194707 | Potter | Aug 2008 | A1 |
20080319387 | Amisar et al. | Dec 2008 | A1 |
20090012220 | Yamane et al. | Jan 2009 | A1 |
20090036768 | Seehusen et al. | Feb 2009 | A1 |
20090062766 | Howlett et al. | Mar 2009 | A1 |
20090101152 | Burk et al. | Apr 2009 | A1 |
20090110844 | Playzer et al. | Apr 2009 | A1 |
20090114327 | Breunig | May 2009 | A1 |
20090117164 | Toreki et al. | May 2009 | A1 |
20090125118 | Gong | May 2009 | A1 |
20090157007 | McKinnon | Jun 2009 | A1 |
20090162530 | Nesbit | Jun 2009 | A1 |
20090176907 | Subramanian et al. | Jul 2009 | A1 |
20090188559 | Nesbit | Jul 2009 | A1 |
20090211909 | Nesbit | Aug 2009 | A1 |
20090220739 | Chougule | Sep 2009 | A1 |
20090226541 | Scholz et al. | Sep 2009 | A1 |
20090281525 | Harding et al. | Nov 2009 | A1 |
20090299452 | Eidenschink et al. | Dec 2009 | A1 |
20090317435 | Vandesteeg et al. | Dec 2009 | A1 |
20090324666 | Krongauz et al. | Dec 2009 | A1 |
20090324738 | Krongauz | Dec 2009 | A1 |
20100015200 | McClain et al. | Jan 2010 | A1 |
20100024648 | Breault | Feb 2010 | A1 |
20100069854 | Okoh et al. | Mar 2010 | A1 |
20100106102 | Ziebol et al. | Apr 2010 | A1 |
20100106103 | Ziebol et al. | Apr 2010 | A1 |
20100135949 | Ou-Yang | Jun 2010 | A1 |
20100136209 | Ou-Yang et al. | Jun 2010 | A1 |
20100137379 | Komori et al. | Jun 2010 | A1 |
20100137472 | Ou-Yang | Jun 2010 | A1 |
20100200017 | Kerr et al. | Aug 2010 | A1 |
20100204648 | Stout et al. | Aug 2010 | A1 |
20100204675 | Woehr et al. | Aug 2010 | A1 |
20100222746 | Burkholz | Sep 2010 | A1 |
20100228178 | McGraw | Sep 2010 | A1 |
20100249713 | Burkholz | Sep 2010 | A1 |
20110009831 | Burkholz et al. | Jan 2011 | A1 |
20110044850 | Solomon et al. | Feb 2011 | A1 |
20110146680 | Conway | Jun 2011 | A1 |
20110150958 | Davis et al. | Jun 2011 | A1 |
20110160662 | Stout et al. | Jun 2011 | A1 |
20110160663 | Stout et al. | Jun 2011 | A1 |
20110218529 | Garcia et al. | Sep 2011 | A1 |
20110301553 | Goral et al. | Dec 2011 | A1 |
20110319825 | Goral et al. | Dec 2011 | A1 |
20120016318 | Hoang et al. | Jan 2012 | A1 |
20120078203 | Gaube et al. | Mar 2012 | A1 |
20120083750 | Sancoucy | Apr 2012 | A1 |
20120103448 | Hopf et al. | May 2012 | A1 |
20120111368 | Rahimy et al. | May 2012 | A1 |
20120277576 | Lui | Nov 2012 | A1 |
20120302997 | Gardner et al. | Nov 2012 | A1 |
20130090607 | McKinnon et al. | Apr 2013 | A1 |
20130090609 | Sonderegger et al. | Apr 2013 | A1 |
20130165867 | Isaacson et al. | Jun 2013 | A1 |
20130165868 | Isaacson et al. | Jun 2013 | A1 |
20130171030 | Ferlic et al. | Jul 2013 | A1 |
20130184679 | Ziebol et al. | Jul 2013 | A1 |
20130196079 | Schwalm et al. | Aug 2013 | A1 |
20130197485 | Gardner et al. | Aug 2013 | A1 |
20130204231 | Ziebol et al. | Aug 2013 | A1 |
20130245568 | Kerr | Sep 2013 | A1 |
20130274686 | Ziebol et al. | Oct 2013 | A1 |
20130310764 | Burkholz et al. | Nov 2013 | A1 |
20130330387 | Ou-Yang | Dec 2013 | A1 |
20140276433 | Woehr | Sep 2014 | A1 |
20160008517 | Burkholz et al. | Jan 2016 | A1 |
20170095596 | Petrak et al. | Apr 2017 | A1 |
Number | Date | Country |
---|---|---|
1331333 | Aug 1994 | CA |
2133053 | Mar 1995 | CA |
2814971 | Apr 2012 | CA |
2905829 | Oct 2014 | CA |
2642540 | Nov 2015 | CA |
2825052 | Aug 2016 | CA |
1187598 | Jul 1998 | CN |
1526771 | Sep 2004 | CN |
1585654 | Feb 2005 | CN |
101353545 | Jan 2009 | CN |
101426539 | May 2009 | CN |
102070983 | May 2011 | CN |
102481391 | May 2012 | CN |
102497894 | Jun 2012 | CN |
103055373 | Apr 2013 | CN |
204684447 | Oct 2015 | CN |
821629 | Nov 1951 | DE |
2104745 | Aug 1972 | DE |
3314640 | Nov 1983 | DE |
3913392 | Oct 1990 | DE |
3913392 | Oct 1991 | DE |
29712676 | Nov 1997 | DE |
202009009602 | Dec 2009 | DE |
102008044296 | Jul 2010 | DE |
0036294 | Sep 1981 | EP |
0070087 | Jan 1983 | EP |
0227230 | Jul 1987 | EP |
0328421 | Aug 1989 | EP |
0338418 | Oct 1989 | EP |
0370997 | May 1990 | EP |
0379271 | Jul 1990 | EP |
0396431 | Nov 1990 | EP |
0414997 | Mar 1991 | EP |
484092 | May 1992 | EP |
0778337 | Nov 1997 | EP |
0992252 | Apr 2000 | EP |
1197242 | Apr 2002 | EP |
1466645 | Oct 2004 | EP |
1679043 | Jul 2006 | EP |
2868722 | May 2015 | EP |
3134161 | Feb 2020 | EP |
S57-501165 | Jul 1982 | JP |
H02-234764 | Sep 1990 | JP |
05277434 | Oct 1993 | JP |
H0747435 | Feb 1995 | JP |
H07051651 | Feb 1995 | JP |
H08-27404 | Jan 1996 | JP |
98182764 | Jul 1996 | JP |
H08209064 | Aug 1996 | JP |
H08311373 | Nov 1996 | JP |
99151262 | Jun 1997 | JP |
H09157548 | Jun 1997 | JP |
H09176677 | Jul 1997 | JP |
99324135 | Dec 1997 | JP |
H10000231 | Jan 1998 | JP |
H10192415 | Jul 1998 | JP |
H11507275 | Jun 1999 | JP |
H11322560 | Nov 1999 | JP |
2000178475 | Jun 2000 | JP |
2000-264803 | Sep 2000 | JP |
2001-072438 | Mar 2001 | JP |
2002510774 | Apr 2002 | JP |
2002-282762 | Oct 2002 | JP |
2003-342402 | Dec 2003 | JP |
2004-043669 | Feb 2004 | JP |
2005-028209 | Feb 2005 | JP |
2005512610 | May 2005 | JP |
2005-515838 | Jun 2005 | JP |
2005-520912 | Jul 2005 | JP |
2006102254 | Apr 2006 | JP |
2007-016096 | Jan 2007 | JP |
2008-533051 | Aug 2008 | JP |
2009-527356 | Jul 2009 | JP |
2009-528360 | Aug 2009 | JP |
2009-544454 | Dec 2009 | JP |
2009542326 | Dec 2009 | JP |
2010-174075 | Aug 2010 | JP |
2010-536836 | Dec 2010 | JP |
2011-528275 | Nov 2011 | JP |
2012-510339 | May 2012 | JP |
2012-510559 | May 2012 | JP |
2012100762 | May 2012 | JP |
2012-532681 | Dec 2012 | JP |
2013-505062 | Feb 2013 | JP |
2013518686 | May 2013 | JP |
2013533005 | Aug 2013 | JP |
2013540486 | Nov 2013 | JP |
2015-519303 | Jul 2015 | JP |
20020066429 | Aug 2002 | KR |
20080039460 | May 2008 | KR |
8200413 | Feb 1982 | WO |
9422522 | Oct 1994 | WO |
9521648 | Aug 1995 | WO |
9616690 | Jun 1996 | WO |
9640359 | Dec 1996 | WO |
9858690 | Dec 1998 | WO |
9858989 | Dec 1998 | WO |
9916498 | Apr 1999 | WO |
9932168 | Jul 1999 | WO |
9934849 | Jul 1999 | WO |
9936490 | Jul 1999 | WO |
9943971 | Sep 1999 | WO |
9944654 | Sep 1999 | WO |
9012171 | Mar 2000 | WO |
0066189 | Nov 2000 | WO |
0074743 | Dec 2000 | WO |
0147592 | Jul 2001 | WO |
0195862 | Dec 2001 | WO |
02051464 | Jul 2002 | WO |
2003041759 | May 2003 | WO |
2004071568 | Aug 2004 | WO |
2004108091 | Dec 2004 | WO |
2005037340 | Apr 2005 | WO |
2006012446 | Feb 2006 | WO |
2006056482 | Jun 2006 | WO |
2006074666 | Jul 2006 | WO |
2006088288 | Aug 2006 | WO |
2006099358 | Sep 2006 | WO |
2006099359 | Sep 2006 | WO |
2006100442 | Sep 2006 | WO |
2007021840 | Feb 2007 | WO |
2007052656 | May 2007 | WO |
2007064835 | Jun 2007 | WO |
2007095576 | Aug 2007 | WO |
2007100653 | Sep 2007 | WO |
2007100776 | Sep 2007 | WO |
2008014438 | Jan 2008 | WO |
2008014447 | Jan 2008 | WO |
2008031601 | Mar 2008 | WO |
2008045761 | Apr 2008 | WO |
2008052790 | May 2008 | WO |
2008128896 | Oct 2008 | WO |
2008132045 | Nov 2008 | WO |
2008152849 | Dec 2008 | WO |
2009012336 | Jan 2009 | WO |
2009055949 | May 2009 | WO |
2009070227 | Jun 2009 | WO |
2009114833 | Sep 2009 | WO |
2010034470 | Apr 2010 | WO |
2010093791 | Aug 2010 | WO |
2011005951 | Jan 2011 | WO |
2011034675 | Mar 2011 | WO |
2011048204 | Apr 2011 | WO |
2011118680 | Sep 2011 | WO |
2012036916 | Mar 2012 | WO |
2013003373 | Jan 2013 | WO |
2013009998 | Jan 2013 | WO |
2013134421 | Sep 2013 | WO |
2013151860 | Oct 2013 | WO |
2014031774 | Feb 2014 | WO |
2014052283 | Apr 2014 | WO |
2015133281 | Sep 2015 | WO |
2015137098 | Sep 2015 | WO |
Entry |
---|
Gama Healthcare, Clinell Alcoholic 2% Chlorhexidine, http//www.gamahealthcare.com/clinellaca2c.html, pp. 1-3, Nov. 7, 2008. |
Enluria, ChloraPrep, http://enluria.com/products/cloraPrep-product.html, pp. 1-3, Oct. 21, 2008. |
Sage Products, Inc , Address Multi-Drug Reistant Organism on the Skin with Early Preop Prep, http://www.sageproducts.com/products/ssi-prevention.cfm, 1 page, Oct. 31, 2008. |
Sage Products, Inc., Preoperative Skin Preparation and Preoperative Oral Care for the Short-Term Ventilated Patient, http://www.sageproducts.com/products/ssi-vap-prevention.cfm, 1 page, Oct. 2008. |
Sage Products, Inc., Preoperative Skin Preparation for the Surgical Patient, http://www.sageproducts.com/products/skin-prep.cfm, 1 page, Oct. 31, 2008. |
ComfortCoat Hydrophilic Coating, DSM in Medical, http://www.dsm.com/en_US/medical/public/home/pages/product-coating-comfortcoat.jsp. Updated Jan. 11, 2013, Printed Apr. 22, 2013. |
Lubricent—Lubricious Hydrophillic Coatings for Medical Devices, Harland Medical Systems, http://www.harlandmedical.com/index.php/materials/lubricent.html, pp. 1-2, Printed Apr. 22, 2013. |
UV & EB Cure, Xiper Innovations, Inc., http://xiperinnovations.com/uv_eb_cure, Printed Apr. 22, 2013. |
Gerald McDonnell and A. Denver Russell, Antiseptics and Disinfectants: Activity, Action and Resistance, Clinical Microbiology Reviews, vol. 12, Jan. 1999, p. 147-179. |
Cabot Corporation, “Using Silicas and Aluminas in Coatins,” www.cabot-corp.com/Silicas-And-Aluminas/Coatings, downloaded from the internet on Apr. 26, 2011. |
Anusavice KJ, Zhang N-Z, Shen C. Controlled Release of Chlorhexidine from UDMA-TEGDMA Resin, Journal of dental research, 2006,85(10); 950-954. |
Ciba Irgacure 500 data sheet from Ciba Specialty Chamicals, online, retrieved on [Dec. 13, 2015]. Retrieved from internet <URL://http://www.conquimica.com/wp-content/uploads/2015/06/ft_irgacure_500.pdf. |
Elson Silva, PhD, “Respecting Hydrology Science in the Patenting System,” pp. 1-7, Jan. 13, 2011. |
Number | Date | Country | |
---|---|---|---|
20190344065 A1 | Nov 2019 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14260027 | Apr 2014 | US |
Child | 16450670 | US |